Illumina Reports Preliminary Q4 Revenue and Adjusted EPS Above Expectations

Gelonghui January 14 | Illumina, a gene sequencing solutions company, announced its preliminary Q4 results, with revenue of $1.155 billion, a year-over-year increase of 5%, surpassing the analysts' expected $11 billion; adjusted earnings per share between $1.27 and $1.3, also higher than the expected $1.21. The company has collaborated with pharmaceutical giants such as AstraZeneca, Merck, and Eli Lilly to launch the world's largest whole-genome genetic perturbation dataset to accelerate AI-driven drug discovery.